Insider Selling: ResMed Inc. (NYSE:RMD) Director Sells 25,934 Shares of Stock

ResMed Inc. (NYSE:RMD) Director John P. Wareham sold 25,934 shares of the company’s stock in a transaction on Friday, January 26th. The stock was sold at an average price of $102.25, for a total value of $2,651,751.50. Following the sale, the director now owns 38,934 shares of the company’s stock, valued at $3,981,001.50. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Shares of ResMed Inc. (RMD) opened at $91.73 on Tuesday. The stock has a market cap of $13,013.51, a P/E ratio of 45.87 and a beta of 0.92. ResMed Inc. has a 12-month low of $67.04 and a 12-month high of $104.78.

ResMed (NYSE:RMD) last released its quarterly earnings results on Monday, January 22nd. The medical equipment provider reported $1.00 earnings per share for the quarter, beating analysts’ consensus estimates of $0.78 by $0.22. ResMed had a net margin of 12.98% and a return on equity of 22.75%. The business had revenue of $601.27 million for the quarter, compared to the consensus estimate of $583.77 million. During the same quarter last year, the firm earned $0.73 EPS. ResMed’s revenue for the quarter was up 13.4% on a year-over-year basis. sell-side analysts expect that ResMed Inc. will post 3.34 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 15th. Investors of record on Thursday, February 8th will be paid a $0.35 dividend. The ex-dividend date of this dividend is Wednesday, February 7th. This represents a $1.40 dividend on an annualized basis and a yield of 1.53%. ResMed’s payout ratio is presently 70.00%.

Several equities research analysts recently weighed in on RMD shares. Zacks Investment Research lowered shares of ResMed from a “buy” rating to a “hold” rating in a research note on Thursday, January 11th. Northland Securities reiterated a “sell” rating and issued a $55.00 price objective on shares of ResMed in a report on Friday, October 27th. BMO Capital Markets increased their price objective on shares of ResMed to $90.00 and gave the company a “market perform” rating in a report on Tuesday, January 23rd. Macquarie cut shares of ResMed from a “neutral” rating to a “sell” rating in a report on Tuesday, January 23rd. Finally, Needham & Company LLC restated a “sell” rating on shares of ResMed in a report on Friday, October 27th. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and four have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $76.00.

A number of large investors have recently bought and sold shares of the stock. YorkBridge Wealth Partners LLC grew its stake in ResMed by 4.9% in the 2nd quarter. YorkBridge Wealth Partners LLC now owns 1,476 shares of the medical equipment provider’s stock valued at $115,000 after buying an additional 69 shares during the last quarter. Toronto Dominion Bank grew its position in ResMed by 12.8% in the 2nd quarter. Toronto Dominion Bank now owns 1,740 shares of the medical equipment provider’s stock worth $135,000 after purchasing an additional 197 shares during the last quarter. Pillar Pacific Capital Management LLC grew its position in ResMed by 1.2% in the 4th quarter. Pillar Pacific Capital Management LLC now owns 43,755 shares of the medical equipment provider’s stock worth $3,706,000 after purchasing an additional 540 shares during the last quarter. Mutual of America Capital Management LLC grew its position in ResMed by 3.6% in the 4th quarter. Mutual of America Capital Management LLC now owns 16,890 shares of the medical equipment provider’s stock worth $1,430,000 after purchasing an additional 591 shares during the last quarter. Finally, WINTON GROUP Ltd grew its position in ResMed by 8.6% in the 3rd quarter. WINTON GROUP Ltd now owns 8,076 shares of the medical equipment provider’s stock worth $622,000 after purchasing an additional 640 shares during the last quarter. Institutional investors and hedge funds own 61.47% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Insider Selling: ResMed Inc. (NYSE:RMD) Director Sells 25,934 Shares of Stock” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another domain, it was illegally stolen and republished in violation of US and international copyright & trademark law. The original version of this story can be accessed at https://www.dispatchtribunal.com/2018/02/13/john-p-wareham-sells-25934-shares-of-resmed-inc-rmd-stock.html.

About ResMed

ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.

Insider Buying and Selling by Quarter for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply